These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations. API Consensus Expert Committee J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350 [TBL] [Abstract][Full Text] [Related]
4. The DOTS strategy for controlling the global tuberculosis epidemic. Frieden TR; Munsiff SS Clin Chest Med; 2005 Jun; 26(2):197-205, v. PubMed ID: 15837105 [TBL] [Abstract][Full Text] [Related]
5. [Multiple drug resistance: a threat for tuberculosis control]. Cardoso EM Rev Panam Salud Publica; 2004 Jul; 16(1):68-73. PubMed ID: 15333267 [TBL] [Abstract][Full Text] [Related]
6. Tuberculosis: a new vision for the 21st century. Small PM Kekkaku; 2009 Nov; 84(11):721-6. PubMed ID: 19999594 [TBL] [Abstract][Full Text] [Related]
7. [How to cope with the global tuberculosis burden--experiences and perspectives for Japan's international cooperation]. Ishikawa N Kekkaku; 2005 Feb; 80(2):89-94. PubMed ID: 15920981 [TBL] [Abstract][Full Text] [Related]
8. Scientific basis of directly observed treatment, short-course (DOTS). Sharma SK; Mohan A J Indian Med Assoc; 2003 Mar; 101(3):157-8, 166. PubMed ID: 14603962 [TBL] [Abstract][Full Text] [Related]
9. Involvement of IMA in tuberculosis control. Chugh S J Indian Med Assoc; 2007 Apr; 105(4):198, 212. PubMed ID: 17822188 [TBL] [Abstract][Full Text] [Related]
10. Rapid DOTS expansion in India. Khatri GR; Frieden TR Bull World Health Organ; 2002; 80(6):457-63. PubMed ID: 12132002 [TBL] [Abstract][Full Text] [Related]
11. Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects. Yew WW Kekkaku; 2011 Jan; 86(1):9-16. PubMed ID: 21401001 [TBL] [Abstract][Full Text] [Related]
12. Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies. Kibret KT; Moges Y; Memiah P; Biadgilign S Infect Dis Poverty; 2017 Jan; 6(1):7. PubMed ID: 28093078 [TBL] [Abstract][Full Text] [Related]
13. WHO identifies 16 countries struggling to control tuberculosis. Wise J BMJ; 1998 Mar; 316(7136):957. PubMed ID: 9550951 [TBL] [Abstract][Full Text] [Related]
14. Current trends in chemotherapy of tuberculosis. Jawahar MS Indian J Med Res; 2004 Oct; 120(4):398-417. PubMed ID: 15520489 [TBL] [Abstract][Full Text] [Related]
15. Dynamics and control of the global tuberculosis epidemic. Bleed D; Dye C; Raviglione MC Curr Opin Pulm Med; 2000 May; 6(3):174-9. PubMed ID: 10782699 [TBL] [Abstract][Full Text] [Related]
16. Fighting the tuberculosis epidemic in the Western Pacific region: current situation and challenges ahead. van Maaren PJ Kekkaku; 2010 Jan; 85(1):9-16. PubMed ID: 20143671 [TBL] [Abstract][Full Text] [Related]
17. Tuberculosis control in Latvia: integrated DOTS and DOTS-plus programmes. Leimane V; Leimans J Euro Surveill; 2006; 11(3):29-33. PubMed ID: 16567876 [TBL] [Abstract][Full Text] [Related]
18. Multi-drug resistant tuberculosis burden and risk factors: an update. Marahatta SB Kathmandu Univ Med J (KUMJ); 2010; 8(29):116-25. PubMed ID: 21209520 [TBL] [Abstract][Full Text] [Related]
19. Multidrug and extensively drug-resistant TB (M/XDR-TB): problems and solutions. Prasad R Indian J Tuberc; 2010 Oct; 57(4):180-91. PubMed ID: 21141336 [TBL] [Abstract][Full Text] [Related]
20. High non-compliance rate with anti-tuberculosis treatment: a need to shift facility-based directly observed therapy short course (DOTS) to community mobile outreach team supervision in Saudi Arabia. AlSahafi AJ; Shah HBU; AlSayali MM; Mandoura N; Assiri M; Almohammadi EL; Khalawi A; AlGarni A; Filemban MK; AlOtaibe AK; AlFaifi AWA; AlGarni F BMC Public Health; 2019 Aug; 19(1):1168. PubMed ID: 31455324 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]